Older adults dying from unintentional falls

Older adults dying from unintentional falls
A new report shows older adults are dying more from unintentional falls leads MedicalWatch for June 19, 2025.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CTV News

37 minutes ago

• CTV News

Sudbury marks 41st Workers' Memorial Day

On Friday in Sudbury, a ceremony was held to mark the 41st anniversary of Workers' Memorial Day at Unifor Local 598. On Friday in Sudbury, a ceremony was held to mark the 41st anniversary of Workers' Memorial Day at Unifor Local 598. The day recognizes the men who were killed at 10:12 a.m. on June 20, 1984, after a seismic event caused a collapse in what was formerly called the Falconbridge Mine. Three workers were killed instantly and one was missing. Rescue teams worked frantically to locate the fourth person, who succumbed to his injuries after a second event caused further delays. Workers' Memorial Day On Friday in Sudbury, a ceremony was held to mark the 41st anniversary of Workers' Memorial Day recognizes the men who were killed at 10:12 a.m. on June 20, 1984, after a seismic event caused a collapse in what was formerly called the Falconbridge Mine. (Amanda Hicks/CTV News) 'It is very important for the local and for the members (and) for the people that were there when a lot of their brothers or sisters were injured or killed on the job,' said Brian McDonald, recording secretary for the pensioners association at Unifor Local 598. 'I knew quite a few of them over the years. And … it's always close to the heart. It's very, very, very emotional for me.' NDP Nickel Belt MPP and NDP health critic France Gelinas was working at the hospital when the accident occurred. Many other sectors need change Gelinas said while there have been many improvements in health and safety since then, more needs to be done. 'We have done a lot in Sudbury to push health and safety forward, mainly in mining and a bit in forestry,' she said. Workers' Memorial Day On Friday in Sudbury, a ceremony was held to mark the 41st anniversary of Workers' Memorial Day recognizes the men who were killed at 10:12 a.m. on June 20, 1984, after a seismic event caused a collapse in what was formerly called the Falconbridge Mine. (Amanda Hicks/CTV News) 'But there are many other sectors where people work, where health and safety are not a priority. But those workers do get hurt, those workers do get injured and some of them even die.' Gelinas said transportation is an area where too many serious accidents are occurring. 'If you look at the number of new drivers that are involved in accidents -- I would say it's not an accident,' she said. 'It's because the health and safety standards that the government should be putting in place are not in place, are lacking. Some of them have even been taken away. And you see there, you see the consequences of that with multiple accidents on all of the roads in the north, not only in the winter but in the summer.' Sudbury Mayor Paul Lefebvre said the day is one of remembrance, while also pushing for change. 'As a community, we are a leader in health and safety, because unfortunately, the people that we have lost, we learn with every experience,' Lefebvre said. 'Certainly, we've got to strive to get better, be better together. And that's why we're here today.' The ceremony was marked by a bagpipe procession, speeches and the laying of flowers at the cenotaph. Related: Memorial day in Sudbury honours workers who were killed on the job Sombre ceremony marks 40th Workers' Memorial Day in Sudbury

Globe and Mail

an hour ago

• Globe and Mail

Obesity Clinical Trials Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment

DelveInsight's, ' Obesity Pipeline Insigh t 2025 ' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Obesity Pipeline Report to explore emerging therapies, key Obesity Companies, and future Obesity treatment landscapes @ Obesity Pipeline Outlook Report Key Takeaways from the Obesity Pipeline Report In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus. In June 2025, Zomagen Biosciences Ltd. conducted a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. In June 2025, Boehringer Ingelheim organized a study is to find out whether a medicine called survodutide (BI 456906) helps people living with obesity disease to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. In June 2025, Novo Nordisk A/S announced a study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. In June 2025, Hanmi Pharmaceutical Company Limited conducted a phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus. DelveInsight's Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment. The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Discover how the Obesity treatment paradigm is evolving. Access DelveInsight's in-depth Obesity Pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies Obesity Emerging Drugs Survodutide: Zealand Pharma Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity. Ecnoglutide: Sciwind Biosciences Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity. CT-868: Carmot Therapeutics CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868's effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity. DD01: D&D Pharmatech DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). The Obesity pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment. Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market. Get a detailed analysis of the latest innovations in the Obesity pipeline. Explore DelveInsight's expert-driven report today! @ Obesity Unmet Needs Obesity Companies Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Obesity Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Obesity Therapies and key Obesity Developments @ Obesity Market Drivers and Barriers, and Future Perspectives Scope of the Obesity Pipeline Report Coverage- Global Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Obesity drug development? Find out in DelveInsight's exclusive Obesity Pipeline Report—access it now! @ Obesity Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Obesity Overview Obesity Pipeline Therapeutics Obesity Therapeutic Assessment Late Stage Products (Phase III) Survodutide: Zealand Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) CT-868: Carmot Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) DD01: D&D Pharmatech Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Obesity Products Obesity Key Companies Obesity Key Products Obesity Unmet Needs Obesity Market Drivers Obesity Market Barriers Obesity Future Perspectives and Conclusion Obesity Analyst Views Obesity Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Globe and Mail

2 hours ago

• Globe and Mail

Dr. Konstantinos Zarkadas Launches National Scholarship to Empower Aspiring Medical Leaders

Transformative Initiative Offers Financial Support to Future Physicians Committed to Service and Excellence GLEN COVE, NEW YORK - June 20, 2025 - In a bold step toward fostering the next generation of compassionate, driven medical professionals, Dr. Konstantinos Zarkadas, a respected leader in the healthcare sector, proudly announces the inauguration of the Dr. Konstantinos Zarkadas Scholarship for Future Doctors. This prestigious national scholarship aims to identify, support, and inspire undergraduate students who exhibit exceptional academic ability, a deep commitment to medicine, and a dedication to improving community health outcomes. The scholarship will award a one-time $1,000 grant to a single undergraduate student who meets the rigorous eligibility criteria. Applications are now open, with the deadline set for November 15, 2025. The recipient will be publicly announced on December 15, 2025. 'The future of medicine depends on individuals who lead with both intellect and empathy,' said Dr. Konstantinos Zarkadas. 'Through this scholarship, I hope to ease the financial burdens faced by aspiring doctors while encouraging them to embrace the calling of medical service with integrity, leadership, and vision. This is not just an award—it is an investment in the future of healthcare.' Dr. Zarkadas brings over two decades of experience in clinical practice and medical leadership. His academic journey, which includes a degree in Psychology from Hunter College, advanced medical training in the Dominican Republic, and a Master of Health Administration from Columbia University, has shaped his unique perspective on holistic and inclusive healthcare delivery. Currently serving as Chief Medical Officer at Arch Sleep Apnea Solutions and leading multiple medical practices, Dr. Konstantinos Zarkadas is deeply committed to transforming community health through culturally competent and patient-centered care. The Dr. Konstantinos Zarkadas Scholarship for Future Doctors has been thoughtfully designed to recognize students who combine academic excellence with a strong sense of social responsibility. Eligible applicants must meet the following criteria: Current Undergraduate Enrollment: Students must be enrolled at an accredited U.S. college or university. Pre-Medical Focus: Candidates must be pursuing a pre-med track or a closely related field, with clear intent to enter medical school. Academic Performance: A minimum cumulative GPA of 3.5 is required. Residency: Open to U.S. citizens and permanent residents. Leadership and Service: Applicants should demonstrate leadership potential and a history of meaningful community involvement. Commitment to Medicine: Candidates must clearly articulate their passion for medicine and dedication to a career in healthcare. Fluent in English, Greek, and Spanish, Dr. Konstantinos Zarkadas has long been an advocate for health equity and multicultural competence in medical practice. His past collaborations with organizations like Somos Community Care ACO and his leadership role in medical education at The New Parkway Hospital underscore his unwavering mission to mentor and empower the next wave of healthcare providers. Unlike many geographically limited programs, this scholarship is open to qualified students nationwide. Applicants must submit an original essay reflecting on their motivation to pursue medicine, their experiences in community service, and their vision for contributing meaningfully to the healthcare field. This narrative component is central to the selection process, allowing students to highlight not only their achievements but their potential for lasting impact. Comprehensive application guidelines and submission instructions can be found at: By championing students who exemplify both academic rigor and humanitarian values, the Dr. Konstantinos Zarkadas Scholarship for Future Doctors seeks to elevate the standards of tomorrow's medical profession. This initiative affirms Dr. Zarkadas's enduring belief that investing in education and ethical leadership is the surest path to a stronger, more inclusive American healthcare system. Media Contact Company Name: Dr. Konstantinos Zarkadas Scholarship Contact Person: Dr. Konstantinos Zarkadas Email: Send Email City: GLEN COVE State: NEW YORK Country: United States Website: